Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes

Thrombosis is a life-threatening complication of diabetes. Platelet reactivity is crucial to thrombus formation, particularly in arterial vessels and in thrombotic complications causing myocardial infarction or ischaemic stroke, but diabetic patients often respond poorly to current antiplatelet medi...

Full description

Bibliographic Details
Main Authors: Arthur, J., Shen, Y., Chen, Younan, Qiao, J., Ni, R., Lu, Y., Andrews, R., Gardiner, E., Cheng, J.
Format: Journal Article
Published: 2013
Online Access:http://hdl.handle.net/20.500.11937/39011
_version_ 1848755474563858432
author Arthur, J.
Shen, Y.
Chen, Younan
Qiao, J.
Ni, R.
Lu, Y.
Andrews, R.
Gardiner, E.
Cheng, J.
author_facet Arthur, J.
Shen, Y.
Chen, Younan
Qiao, J.
Ni, R.
Lu, Y.
Andrews, R.
Gardiner, E.
Cheng, J.
author_sort Arthur, J.
building Curtin Institutional Repository
collection Online Access
description Thrombosis is a life-threatening complication of diabetes. Platelet reactivity is crucial to thrombus formation, particularly in arterial vessels and in thrombotic complications causing myocardial infarction or ischaemic stroke, but diabetic patients often respond poorly to current antiplatelet medication. In this study, we used a nonhuman primate model of Type 1 diabetes to measure early downstream signalling events following engagement of the major platelet collagen receptor, glycoprotein (GP)VI. Diabetic monkeys were given enough insulin to maintain their blood glucose levels either at 8 mM (well-controlled diabetes) or 15 mM (poorly controlled diabetes). Flow cytometric analysis was used to measure platelet reactive oxygen species (ROS) generation, calcium mobilisation, receptor surface expression, and immature platelet fraction. We observed exacerbated intracellular ROS and calcium flux associated with engagement of GPVI in monkeys with poorly controlled diabetes. GPVI surface levels did not differ between healthy monkeys or the two diabetic groups. Treatment of platelets with the specific Syk inhibitor BAY61-3606 inhibited GPVI-dependent ROS and, importantly, reduced ROS generation in the poorly controlled diabetes group to that observed in healthy monkeys. These data indicate that glycaemic control is important in reducing GPVI-dependent platelet hyperreactivity and point to a potential antithrombotic therapeutic benefit of Syk inhibition in hyperglycaemic diabetes. © 2013 J. F. Arthur et al.
first_indexed 2025-11-14T08:56:53Z
format Journal Article
id curtin-20.500.11937-39011
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:56:53Z
publishDate 2013
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-390112017-09-13T14:22:14Z Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes Arthur, J. Shen, Y. Chen, Younan Qiao, J. Ni, R. Lu, Y. Andrews, R. Gardiner, E. Cheng, J. Thrombosis is a life-threatening complication of diabetes. Platelet reactivity is crucial to thrombus formation, particularly in arterial vessels and in thrombotic complications causing myocardial infarction or ischaemic stroke, but diabetic patients often respond poorly to current antiplatelet medication. In this study, we used a nonhuman primate model of Type 1 diabetes to measure early downstream signalling events following engagement of the major platelet collagen receptor, glycoprotein (GP)VI. Diabetic monkeys were given enough insulin to maintain their blood glucose levels either at 8 mM (well-controlled diabetes) or 15 mM (poorly controlled diabetes). Flow cytometric analysis was used to measure platelet reactive oxygen species (ROS) generation, calcium mobilisation, receptor surface expression, and immature platelet fraction. We observed exacerbated intracellular ROS and calcium flux associated with engagement of GPVI in monkeys with poorly controlled diabetes. GPVI surface levels did not differ between healthy monkeys or the two diabetic groups. Treatment of platelets with the specific Syk inhibitor BAY61-3606 inhibited GPVI-dependent ROS and, importantly, reduced ROS generation in the poorly controlled diabetes group to that observed in healthy monkeys. These data indicate that glycaemic control is important in reducing GPVI-dependent platelet hyperreactivity and point to a potential antithrombotic therapeutic benefit of Syk inhibition in hyperglycaemic diabetes. © 2013 J. F. Arthur et al. 2013 Journal Article http://hdl.handle.net/20.500.11937/39011 10.1155/2013/370212 unknown
spellingShingle Arthur, J.
Shen, Y.
Chen, Younan
Qiao, J.
Ni, R.
Lu, Y.
Andrews, R.
Gardiner, E.
Cheng, J.
Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes
title Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes
title_full Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes
title_fullStr Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes
title_full_unstemmed Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes
title_short Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes
title_sort exacerbation of glycoprotein vi-dependent platelet responses in a rhesus monkey model of type 1 diabetes
url http://hdl.handle.net/20.500.11937/39011